Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial
Research Square February 23, 2026 Rotem Petranker, Norman A. S. Farb, Omer A. Syed et al. preprint
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two...
DOI: 10.21203/rs.3.rs-8319478/v1 (opens in new tab)
Full text (opens in new tab)
Psilocybin
Major depressive disorder
Placebo
Adverse effect
+9